AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03865511 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tumor biopsies
Description: Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications).
Study NCT03865511 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Description: ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations
Study NCT01392378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Study NCT01392378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INFANRIX hexa
Description: INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Study NCT01392378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Study NCT00989508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo marked PEXSIG
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study NCT02826616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
Study NCT02468232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
Study NCT02468232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
Study NCT02468232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to LCZ696
Description: LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
Study NCT02468232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Enalapril
Description: Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
Study NCT04497493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)-active
Description: Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
Study NCT04497493 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)-sham
Description: Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
Study NCT02621437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy sessions
Description: - Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
Study NCT02621437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone questionnaires
Description: Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire
Study NCT02621437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: phone questionnaires
Description: Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire
Study NCT03363178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3107
Description: BCG Vaccine, 0.1mL
Study NCT02020590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB® implantation
Description: Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
Study NCT02453893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Study NCT01986283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsule
Description: Taken once
Study NCT01986283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 40 mg capsule swallowed whole, taken once
Study NCT02453893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT05345548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cold Pressor test
Description: Cold Pressor test will be done for 3 minute duration maximum
Study NCT03819257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoanal ultrasound
Description: For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
Study NCT03819257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution anorectal manometry
Description: 1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension.
Study NCT03819257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Balloon expulsion test
Description: A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
Study NCT01986283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 40 mg capsule chewed, taken once
Study NCT01986283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 40 mg solution, taken once
Study NCT03821883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablet
Description: Aspirin 100mg qd
Study NCT01392378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Study NCT01392378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
Study NCT03922061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
Study NCT03922061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV
Description: fractional-dose inactived polio vaccine
Study NCT03922061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fIPV
Description: fractional-dose inactived polio vaccine
Study NCT01186159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: 40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
Study NCT01392378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
Study NCT00813618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study NCT00813618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study NCT00813618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
Study NCT02447120 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT machines used for diagnostic purposes
Study NCT01617655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study NCT00889707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: 1000/1200mg po daily for 4 weeks
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000/1200mg po daily for 4 weeks
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: 180 micrograms sc weekly for 4 weeks
Study NCT01617655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Study NCT01617655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT01617655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT03224585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days
Study NCT03224585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days
Study NCT00517283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide and placebo
Description: Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
Study NCT00517283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide and placebo
Description: Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
Study NCT00517283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide and placebo
Description: Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
Study NCT01883869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT01883869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03965793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated management of hypotension
Description: Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
Study NCT03965793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated management of hypotension
Description: Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
Study NCT02633839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Description: Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
Study NCT02633839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.
Study NCT04387526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (SOF and DCV)
Study NCT04387526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (SOF, DCV, and RBV)
Study NCT00889707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study NCT02590536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet.
Study NCT02590536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03465722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avapritinib
Description: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
Study NCT03465722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
Study NCT03172273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular intrahepatic portosystemic shunt with covered PTFE
Study NCT03172273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: paracentasis plus albumine invision
Study NCT00527618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: valacyclovir 1000 mg orally twice daily for 12 weeks.
Study NCT00527618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: acyclovir 400 mg orally twice daily for 12 weeks.
Study NCT00363142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-boosted Fosamprenavir
Description: Once daily, reduced dose ritonavir-boosted fosamprenavir
Study NCT00363142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full Boosted Fosamprenavir
Description: Full ritonavir-boosted fosamprenavir
Study NCT02881775 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS and exercise
Description: rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
Study NCT02881775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS and exercise
Description: rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
Study NCT02881775 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS and exercise
Description: rTMS unit is on and running but mu metal is placed between the coil and the skull
Study NCT02881775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS and exercise
Description: rTMS unit is on and running but mu metal is placed between the coil and the skull
Study NCT02267889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image guided GP ablation
Description: 3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
Study NCT02267889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-SPECT dedicated cardiac nuclear camera
Study NCT01655186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Study NCT01655186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02156024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrodia and Uncaria Drink
Description: Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
Study NCT01022970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAX576 placebo
Study NCT01637870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena negative pressure wound system
Description: Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
Study NCT01244958 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg Rituximab infusion
Study NCT00377182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048 1500mg
Description: 1500mg po bid for 4 weeks
Study NCT01244958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion of Sodium citrate, Polysorbate, Sodium chloride
Study NCT03276013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab in combination with doxorubicin
Study NCT03427450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.